Christopher Dufton, Ph.D.

Christopher Dufton, Ph.D.


Christopher Dufton

Dr. Dufton brings over 25 years of clinical research and development experience, primarily focused on cardiovascular and pulmonary diseases. Prior to joining InCarda, Chris was Vice-President of Clinical Development at ARCA biopharma, where he led development of a genetically targeted therapy for atrial fibrillation in patients with heart failure. He also served as Director of Clinical Research at Gilead Sciences, where he led a cross-functional team responsible for Phase 4 development of Letairis® (ambrisentan) for pulmonary hypertension and idiopathic pulmonary fibrosis.

Prior to joining Gilead, he directed the ambrisentan program at Myogen, where he oversaw Phase 1-3 development leading to the accelerated approval of Letairis® for the treatment of pulmonary hypertension. Earlier in his career, he conducted oncology research at the University of Colorado Hospital/Medical School. Dr. Dufton has also been a consultant to the biopharmaceutical industry for such clients as Genentech and United Therapeutics.

Dr. Dufton received his Ph.D. in molecular and cellular biology from the University of Colorado and holds a B.A. degree in biochemistry from Rutgers University.

For more information about InCarda: